Arcturus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- $557.6M
- Website
- http://www.arcturusrx.com
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- SARS-CoV-2
- Interventions
- Biological: ARCT-021 Dose 1Biological: ARCT-021 Dose 2Biological: ARCT-021 Dose Regimen 1Biological: ARCT-021 Dose 3Biological: ARCT-021 Dose 4Biological: ARCT-021 Dose Regimen 2Other: Placebo
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT04480957
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore, Singapore
Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency
Phase 1
Completed
- Conditions
- Ornithine Transcarbamylase Deficiency
- Interventions
- Other: PlaceboBiological: ARCT-810
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04442347
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇺🇸Children's Wisconsin - Milwaukee Hospital, Milwaukee, Wisconsin, United States
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Ornithine Transcarbamylase Deficiency
- Interventions
- Biological: ARCT-810Other: Placebo
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04416126
- Locations
- 🇳🇿
Auckland Clinical Studies (ACS) Ltd., Auckland, New Zealand
© Copyright 2025. All Rights Reserved by MedPath